| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Sinovac Biotech Ltd.
13D/A
SVA · P8696W104
|
15.0% |
12/17/2025
Event 12/15/2025
|
||||
| SAIF Partners IV L.P. | 15.0% | |||||
| Saif IV GP, L.P. | 15.0% | |||||
| SAIF IV GP Capital Ltd. | 15.0% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Amprius Technologies, Inc.
13G/A
AMPX · 03214Q108
|
0% |
8/14/2025
Event 6/30/2025
|
||||
| SAIF Partners IV L.P. | 0% | |||||
| Saif IV GP, L.P. | 0% | |||||
| SAIF IV GP Capital Ltd. | 0% | |||||
| Andrew Y. Yan | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.